ERBB2 and breast carcinoma: The licensing of olaparib was extended to gBRCA1/2 m, high-risk, HER2-negative early breast cancer following the results of the phase III OlympiA trial which observed a 4-year OS benefit in patients treated with olaparib versus placebo [34].